Supplement AERs Require Less Forgiving Risk/Benefit Calculation - FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
While approved drugs are backed by thorough clinical histories detailing expected adverse events, the same body of clinical knowledge is not available for supplements, which " inserts much more uncertainty into the equation," says CFSAN dietary supplement official Robert Moore.